S2-E30.1 – The Global Liver Institute US NASH Action Plan — Overview And What Education Must Achieve

Global Liver Institute Director of Global Policy Andrew Scott, Madrigal Pharmaceuticals Co-Founder and CMO Becky Taub, and Central Virginia VA Health Care System Chief of Hepatology and Gastroenterology Dr. Michael Fuchs discuss GLI's US NASH Action Plan and steps different stakeholders can take to support the Plan. In this conversation, Andrew discusses the genesis of the US NASH Action Plan and the group begins to discuss education and awareness opportunities.

Andrew Scott walks a group of engaged stakeholders through Global Liver Institute’s reasoning about developing the plan in the first place, the Plan’s four key platforms and some early progress with legislation and developing local leaders. The other Surfers ask questions and then begin to share their own perspectives, with Louise Campbell reiterating the vital importance educating families and Stephen Harrison identifying a set of physician targets for NASH education.

This conversation is sponsored by a grant from Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is leading the field of NASH therapeutic development with resmetirom, a thyroid receptor beta agonist with potential to address both the liver pathophysiology and fibrosis caused by NASH.

TOPICS: AASLD, cirrhosis, Diabetes, Diagnostic Tests, DrugTrial, education, Fatty Liver, FDA, Global Liver Institute, Madrigal, NAFLD, NASH, non-invasive liver testing, Obesity, Patient Advocacy, PNAFLD, social policy,

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

Experience Nudge Learning! Interested in a new way of learning?